Apple: Analysts' Upgrades, Downgrades

Best Buy (BBY) target upped at Deutsche. BBY target was boosted to $48. Several data points suggest weaker sales. Buy rating.

Bristol-Myers (BMY) estimates cut at Morgan Stanley. BMY estimates were lowered through 2011. ZGEN deal will take away from earnings. Neutral rating and $27 price target.

Biovail (BVF) target boosted at Deutsche. Shares of BVF now seen reaching $27. Valeant purchase could carry more synergies. Buy rating.

Dryships (DRYS) estimates, target lowered at Jefferies. DRYS estimates were cut through 2011. Equity offering will dilute earnings. Hold rating and new $4 price target.

Fedex (FDX) price target raised at Barclays. FDX price target increased to $109 from $106. Healthy industrial economy combined with lower fuel sets the stage for FDX to beat guidance. Maintain Neutral rating.

Foot Locker (FL) target cut at Morgan Stanley to $12. Company is losing market share and continues to invest in the business. Underweight rating.

Eli Lilly (LLY) target lowered at Morgan Stanley to $32. Company could face some lower product sales. Underweight rating.

Lowe's (LOW) target increased at Goldman to $25. Company deserves a higher multiple. Buy rating.

McDonald's (MCD) target raised at Deutsche to $83. Company continues to post strong sales momentum. Buy rating.

Nasdaq (NDAQ) estimates reduced at UBS through 2011. Company is seeing lower volumes across the board. Neutral rating and $21 price target.

NYSE Euronext (NYX) target lowered at UBS. Shares of NYX now seen reaching $39. Company is seeing lower US equity volumes. Buy rating.

Penn National Gaming (PENN) price target boosted at Barclays to $36 from $34 as launch of Charles Town table games has exceeded expectations. Reiterate Overweight rating.

Petsmart (PETM) target boosted at Goldman to $38. Company deserves a higher multiple. Neutral rating.

Texas Capital Bancshares (TCBI) estimates cut at Credit Suisse. TCBI 2010 and 2011 EPS estimates lowered to $0.87 and $1.26, respectively. Higher provisioning levels associated with construction loan exposure, Credit Suisse said. Maintain Outperform rating and $21 price target.

>To order reprints of this article, click here: Reprints